Response to direct‐acting antivirals for hepatitis C treatment in vertically HIV/HCV co‐infected patients

Carrasco, Itzíar; Sainz, Talía; Frick, Marie Antoinette; Ory, Santiago Jiménez de; Fortuny, Clàudia; Burgos, Joaquín; Montero, Marta; Gavilán, César; Falcón, María Dolores; Couceiro, José Antonio; Bernardino, José I.; Bisbal, Otilia; Guerrero, Carmelo; Aldámiz‐Echevarría, María Teresa; Berenguer, Juan; Navarro, Marı́a Luisa

doi:10.1111/jvh.13308

Cited by 9 publications

(13 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, direct acting antivirals (DAAs) have been approved for the treatment of all HCV-infected children aged 12 to 17 years. DAAs are a safe and effective option in perinatally infected HIV/HCV patients; therapy should be started early to prevent disease progression [ 91 , 92 ].…”

Section: Hepatopancreatic Disordersmentioning

confidence: 99%

Gastrointestinal Diseases in Children Living with HIV

2021

View full text Add to dashboard Cite

Thanks to the advances in antiretroviral therapies (ART) and early diagnosis, pediatric HIV has turned into a chronic infection that requires the collaboration of all pediatric subspecialists for holistic patient management. Gastrointestinal complaints are a frequent reason for seeking access to medical care in all pediatric patients worldwide. Intestinal involvement is present in virtually all children with HIV infections. In high-prevalence settings, up to 25% of children accessing the hospital for diarrhea are diagnosed with HIV. More than half of patients with advanced disease present with gastrointestinal symptoms, from mild infectious diarrhea to severe gastrointestinal impairment, malabsorption and failure to thrive. Gastrointestinal disorders do not spare children on ART, particularly in the initial months of therapy. ART-associated pancreatitis and hepatitis are rare but potentially severe adverse events, whereas lower abdominal symptoms have been reported in more than a third of patients. The latter are usually mild and transient, but may limit ART adherence; a correct framing of the problem is necessary to minimize therapy switches while optimizing the quality of life of children on ART. This review aims to provide state-of-the-art guidance for the initial approach to gastrointestinal diseases in children living with HIV.

show abstract

Section: Hepatopancreatic Disordersmentioning

confidence: 99%

Gastrointestinal Diseases in Children Living with HIV

2021

View full text Add to dashboard Cite

show abstract

“…The FDA has cleared this combination of monoclonal antibodies to SARS-COV-2 on an emergency basis (REGEN-COV) for co-administration by intravenous or subcutaneous injection for the treatment of mild to moderate COVID-19 in individuals over 12 years of age and weighing no less than 40 kg who are at high risk for progression to severe COVID-19 [61,62]. Traditional risk groups would also include overweight patients or pregnant women, as well as those suffering from cardiovascular disease, hypertension or chronic respiratory disease (Table 1) [61,63,64].…”

Section: Casirivimab + Imdevimabmentioning

confidence: 99%

“…FDA clearance was based on interim Phase 1/2 results from a double-blind trial (COV-2067) in which 799 outpatients with mild to moderate COVID-19 were randomized in a blinded fashion to receive a single intravenous infusion of monoclonals or placebo. Outcomes were assessed 28 days after infusion [64] and viral load at day 7 was significantly lower with the monoclonal combination than with placebo. There was also less need for hospitalization, emergency department visit or teleconsultation within 28 days after infusion (2.8% vs. 6.5%).…”

Section: Combination Of Neutralizing Monoclonal Antibodies Brii-196 A...mentioning

confidence: 99%

“…The combination is protective against variants of concern known to date [65]. Subsequent data in Phase 3 studies (COV-2067), in which 3,867 patients with mild or moderate COVID and at least one risk factor for progression to severe disease were randomized prompted the FDA to change the licensed dose of casirivimab and imdevimab from 1200 mg to 600 mg of each antibody [64,66].…”

Section: Combination Of Neutralizing Monoclonal Antibodies Brii-196 A...mentioning

confidence: 99%

See 1 more Smart Citation

Untitled

2022

Rev Esp Quimioter

View full text Add to dashboard Cite

show abstract

“…A 12-wk course with sofosbuvir/ledipasvir was found to allow autologous HSC-GT for the correction of severe combined immunodeficiency caused by adenosine deaminase deficiency as described in a pioneering study[ 59 ]. Pediatric studies have not yet replicated the encouraging results with DAA in adults with HIV/HCV coinfection[ 60 - 62 ], even when vertically transmitted[ 63 ], nor for the treatment of HCV in hemodialyzed[ 64 ] and kidney transplant patients[ 65 , 66 ].…”

Section: Hcv Treatment Of Hcv In Children At Riskmentioning

confidence: 99%

Breakthroughs and challenges in the management of pediatric viral hepatitis

Nicastro

Norsa

Giorgio

et al. 2021

WJG

View full text Add to dashboard Cite

Chronic infections by hepatitis B virus (HBV) and hepatitis C virus (HCV) major causes of advanced liver disease and mortality worldwide. Although regarded as benign infections in children, their persistence through adulthood is undoubtedly of concern. Recent advances in HCV treatment have restored the visibility of these conditions and raised expectations for HBV treatment, which is currently far from being curative. Herein we describe direct-acting antivirals available for pediatric HCV (sofosbuvir/ledipasvir, sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) and their real-world use. A critical review of the HBV pediatric classification is provided. Anti-HBV investigational compounds are reviewed in light of the pathophysiology in the pediatric population, including capsid assembly modulators, antigen secretion inhibitors, silencing RNAs, and immune modifiers. Recommendations for screening and management of immunosuppressed children or those with other risk factors or comorbidities are also summarized.

show abstract

Response to direct‐acting antivirals for hepatitis C treatment in vertically HIV/HCV co‐infected patients

Cited by 9 publications

References 7 publications

Gastrointestinal Diseases in Children Living with HIV

Gastrointestinal Diseases in Children Living with HIV

Untitled

Breakthroughs and challenges in the management of pediatric viral hepatitis

Contact Info

Product

Resources

About